Sarepta Therapeutics
(SRPT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 383,622 | 427,290 | 428,430 | 541,932 | 851,929 |
| Marketable Securities | 1,076,852 | 963,453 | 1,247,820 | 1,191,610 | 1,008,786 |
| Receivables | 359,997 | 378,806 | 400,327 | 318,855 | 236,808 |
| Inventories | 485,795 | 373,530 | 322,859 | 244,011 | 226,876 |
| Other current assets | 377,370 | 321,786 | 179,895 | 154,441 | 148,215 |
| TOTAL | $2,683,636 | $2,464,865 | $2,579,331 | $2,450,849 | $2,472,614 |
| Non-Current Assets | |||||
| PPE Net | 276,200 | 249,302 | 227,154 | 212,367 | 188,874 |
| Other Non-Current Assets | 464,421 | 510,218 | 458,091 | 446,491 | 464,402 |
| TOTAL | $740,621 | $759,520 | $685,245 | $658,858 | $653,276 |
| Total Assets | $3,424,257 | $3,224,385 | $3,264,576 | $3,109,707 | $3,125,890 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 91,505 | 105,586 | 105,483 | N/A | N/A |
| Accounts payable and accrued liabilities | 107,417 | 91,536 | 164,918 | 87,948 | 109,796 |
| Accrued Expenses | 350,404 | 283,317 | 314,997 | 322,350 | 326,877 |
| Other current liabilities | 17,128 | 16,270 | 17,845 | 17,951 | 16,992 |
| TOTAL | $688,490 | $608,709 | $653,659 | $450,743 | $498,654 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,134,810 | 1,133,660 | 1,132,515 | 1,236,755 | 1,235,517 |
| Deferred Revenues | 122,036 | 112,000 | 50,416 | 22,494 | 44,989 |
| Other Non-Current Liabilities | 198,888 | 195,824 | 182,065 | 172,852 | 165,308 |
| TOTAL | $1,658,698 | $1,654,484 | $1,751,580 | $1,894,607 | $1,885,825 |
| Total Liabilities | $2,347,188 | $2,263,193 | $2,405,239 | $2,345,350 | $2,384,479 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 95,366 | 94,524 | 93,855 | 93,547 | 93,279 |
| Common Shares | 10 | 9 | 9 | 9 | 9 |
| Retained earnings | -4,403,634 | -4,410,094 | -4,446,213 | -4,491,868 | -4,450,931 |
| Other shareholders' equity | -1,030 | -691 | 918 | -638 | -1,055 |
| TOTAL | $1,077,069 | $961,192 | $859,337 | $764,357 | $741,411 |
| Total Liabilities And Equity | $3,424,257 | $3,224,385 | $3,264,576 | $3,109,707 | $3,125,890 |